ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Lyka Labs was fined ₹1.62 Lakhe by NSE for delayed FY 2025-26 Annual Report filing. The company has rectified the lapse and will pay within 15 days.
Lyka Labs filed its quarterly shareholding pattern for the period ended September 30, 2026 under Regulation 31. Promoter and public holdings are reported as of that date, with no transaction or corporate event.
Lyka Labs re-appointed Neeraj Golas as Non-Executive Independent Director for 36 months, effective 16 January 2027. The board approved it at its 30 October 2026 meeting.
Q2 FY27 standalone revenue rose 34.06% to Rs. 4,419.95 Lacs. Standalone net profit swung to Rs. 131.50 Lacs from a loss.
Lyka Labs approved unaudited standalone results for the half year ended 30 September 2026. The board also sought postal ballot approval for an independent director's reappointment.
Lyka Labs has intimated that its Board will meet on 30 October 2026 to consider Q2 FY27 unaudited financial results. No decisions or figures are reported in this prior intimation.
Lyka Labs Limited submitted a revised press release for Q1 FY27 results to correct typographical errors. The company reported a consolidated net profit of Rs. 2.05 Crore.
Lyka Labs Limited conducted its 47th Annual General Meeting on August 10, 2026. Shareholders transacted business including the adoption of financial statements and approval of related party transactions.
Lyka Labs Limited reported its Q1 FY27 results with consolidated net total income of Rs. 42.73 Crore. Standalone net profit surged 159% year-on-year to Rs. 2.10 Crore.
Lyka Labs Ltd reported revenue from operations of ₹42.3 Cr (+28.2% YoY) and net profit of ₹2 Cr (+100.0% YoY) for Q1 FY27.
Lyka Labs Ltd scheduled a board meeting for August 10, 2026. The meeting will consider the Q1 unaudited financial results.
Lyka Labs allotted 462,711 equity shares following an NCLT-approved amalgamation with Lyka Exports, as disclosed in this quarterly shareholding pattern filing.
Lyka Labs issued a notice for its 47th AGM scheduled for August 10, 2026. Key agendas include approving Rs. 75 Crore in related party transactions.
Lyka Labs submitted its 47th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for August 10, 2026, via video conferencing.
Lyka Labs convened its 47th AGM for August 10, 2026. Agenda includes approving a Rs. 75 Crore related party transaction limit with IPCA Laboratories.
Promoter Kunal Gandhi and related parties bought 55,967 shares on the open market. Their stake now equals 16.19% of Lyka Labs.
Promoter Kunal Gandhi acquired 6,533 shares via open market for ₹0.46 Crore. Another acquisition of 5,000 shares was reported for Alisha Gandhi.
Lyka Labs allotted 4,62,711 equity shares to shareholders of Lyka Exports under a sanctioned scheme. This completes the amalgamation and increases paid-up capital to Rs.36.15 Crore.
Lyka Labs Ltd clarified to BSE that no material event caused the recent price movement. The company confirms all required disclosures are up to date.
Lyka Labs received a favorable NCLAT order to recover ₹0.63 Crore from Modi Life Care Industries Limited. The payment must be received within thirty days.
Lyka Labs Ltd reported revenue from operations of ₹28 Cr (-16.2% YoY) and a net loss of ₹8.1 Cr for Q4 FY26.
Lyka Labs reported audited FY26 results alongside a ₹23.01 Crore impairment on its subsidiary investment. Net loss widened significantly due to this exceptional charge.